{"id":"W4380079804","doi":"10.1002/hon.3164_441","title":"CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Queen's University; Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Loxo Oncology; AbbVie Canada; National Institutes of Health; Pharmacyclics; National Comprehensive Cancer Network; Breast Cancer Research Foundation; TG Therapeutics; Regeneron Pharmaceuticals; Genentech; Celgene; Gilead Sciences","keywords":"Medicine; Salvage therapy; Internal medicine; Gemcitabine; Rituximab; Oncology; Follicular lymphoma; Lymphoma; Refractory (planetary science); Gastroenterology; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003077855,0.001263515,0.001470422,0.0004985257,0.0008399492,0.0009368869,0.00151237,0.001506763,0.01095143],"category_scores_gemma":[0.001201903,0.0006121781,0.0007666163,0.0008596511,0.0004344116,0.0004362271,0.0005368451,0.001853941,0.002974632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002216967,"about_ca_system_score_gemma":0.004894468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004850125,"about_ca_topic_score_gemma":0.0157781,"domain_scores_codex":[0.9990041,0.0006759917,0.00005346875,0.00006455679,0.00008289476,0.0001190669],"domain_scores_gemma":[0.9992697,0.00008448529,0.0001753548,0.00008448738,0.0001064195,0.0002795946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4687578,0.01851109,0.01452975,0.006455785,0.001703734,0.0006137386,0.0005589715,0.003911,0.06682207,0.002531418,0.1902052,0.2253994],"study_design_scores_gemma":[0.6677095,0.08741581,0.04857117,0.0007869824,0.0009913149,0.00105006,0.0001290022,0.002444248,0.008638857,0.0007651803,0.1814272,0.00007070477],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.4733544,0.02233099,0.008880257,0.0065575,0.001158599,0.3461304,0.08274479,0.001241838,0.05760133],"genre_scores_gemma":[0.4631571,0.01214567,0.02678269,0.00594075,0.0008372876,0.3645038,0.1011293,0.0003622996,0.02514105],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.01095143,"threshold_uncertainty_score":0.03663617,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09117545114869888,"score_gpt":0.3840070893897315,"score_spread":0.2928316382410326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}